Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Lead Sponsor:

NCIC Clinical Trials Group

Conditions:

Colorectal Cancer

Lung Cancer

Eligibility:

All Genders

18-120 years

Phase:

PHASE1

Brief Summary

RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways ...

Detailed Description

OBJECTIVES: * Determine the recommended phase II dose of AZD2171 when administered with standard combination chemotherapy in patients with advanced non-small cell lung cancer or colorectal cancer. * ...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically or cytologically confirmed diagnosis of 1 of the following:
  • Non-small cell lung cancer (NSCLC), meeting 1 of the following criteria:
  • Stage IIIB disease
  • No pleural effusion and not a candidate for a combined modality treatment
  • Stage IV disease
  • Local or metastatic failure after surgery and/or radiotherapy
  • Colorectal cancer (CRC)
  • Advanced and/or metastatic disease
  • Suitable for first-line therapy with oxaliplatin, leucovorin calcium, and fluorouracil (FOLFOX-6)
  • Clinically or radiologically documented disease
  • No tumor marker elevation as sole evidence of disease
  • No necrotic/hemorrhagic metastases or tumor
  • No untreated brain or meningeal metastases
  • Previously treated, radiologic or clinical evidence of stable brain metastases allowed provided disease is asymptomatic and corticosteroids are not required
  • PATIENT CHARACTERISTICS:
  • ECOG performance status 0-2
  • Hemoglobin normal
  • Absolute granulocyte count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min
  • Bilirubin ≤ 1.5 times ULN
  • AST or ALT ≤ 2 times ULN (5 times ULN if liver involvement)
  • Proteinuria ≤ grade 1
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of other malignancies except adequately treated nonmelanoma skin cancer or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
  • No untreated and/or uncontrolled cardiovascular conditions or symptomatic cardiac dysfunction
  • No resting blood pressure (BP) consistently higher than systolic BP \> 150 mm Hg and diastolic BP \> 100 mm Hg (in the presence or absence of a stable dose of antihypertensive medication)
  • No poorly controlled hypertension, history of labile hypertension, or poor compliance with antihypertensive medication
  • No overt bleeding (≥ 30 mL bleeding/episode) within the past 3 months
  • No clinically relevant hemoptysis (≥ 5 mL fresh blood) within the past 4 weeks
  • Flecks of blood in sputum allowed
  • No active or uncontrolled infections
  • No serious illnesses or medical conditions that would preclude compliance with study requirements
  • No mean QTc with Bazett's correction \> 470 msec
  • No history of familial long QT syndrome
  • No peripheral neuropathy \> grade 1
  • No dihydropyrimidine dehydrogenase deficiency or history of severe hand-foot syndrome after fluoropyrimidines (for patients with CRC)
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • Recovered from prior therapy
  • At least 6 months since prior adjuvant or neoadjuvant therapy
  • At least 6 months since prior adjuvant radiotherapy
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin C) (for patients with NSCLC)
  • At least 4 weeks since prior and no concurrent corticosteroids
  • At least 3 weeks since prior palliative radiotherapy and recovered
  • Concurrent palliative radiotherapy allowed
  • At least 2 weeks since prior epidermal growth factor receptor inhibitor therapy
  • At least 2 weeks since prior major surgery
  • No more than 1 prior single-agent, nonplatinum-containing chemotherapy regimen for metastatic disease (for patients with NSCLC)
  • No prior gemcitabine hydrochloride (for patients with NSCLC)
  • No prior oxaliplatin (for patients with CRC)
  • No prior angiogenesis inhibitor
  • No prior chemotherapy for advanced/metastatic disease (for patients with CRC)
  • No other concurrent experimental drugs or anticancer therapy

Exclusion

    Key Trial Info

    Start Date :

    November 29 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 22 2008

    Estimated Enrollment :

    31 Patients enrolled

    Trial Details

    Trial ID

    NCT00343408

    Start Date

    November 29 2005

    End Date

    September 22 2008

    Last Update

    August 4 2023

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Ottawa Hospital Regional Cancer Centre - General Campus

    Ottawa, Ontario, Canada, K1H 8L6

    2

    Princess Margaret Hospital

    Toronto, Ontario, Canada, M5G 2M9

    3

    Jewish General Hospital - Montreal

    Montreal, Quebec, Canada, H3T 1E2